Cognitive dysfunction in SLE: development of a screening tool
Background. Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). There are two methods which have been used to detect CD in patients with SLE: traditional neuropsychological tests (NPT) and the Automated Neuropsychological Assessm...
Gespeichert in:
| Veröffentlicht in: | Lupus 2011-10, Vol.20 (11), p.1142-1146 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1146 |
|---|---|
| container_issue | 11 |
| container_start_page | 1142 |
| container_title | Lupus |
| container_volume | 20 |
| creator | Adhikari, T Piatti, A Luggen, M |
| description | Background. Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). There are two methods which have been used to detect CD in patients with SLE: traditional neuropsychological tests (NPT) and the Automated Neuropsychological Assessment Metrics (ANAM). Both are time-consuming and neither is readily available for screening purposes.
Purpose. The aim of our study was to evaluate the Montreal Cognitive Assessment (MoCA) test as a screening tool for detection of CD in SLE.
Methods. SLE patients fulfilling ACR criteria were administered the ANAM, a computerized test battery which measures various cognitive domains and the MoCA, a one-page, performance-based screening test designed to detect mild cognitive impairment in the elderly. With the ANAM as the gold standard, the performance characteristics of the MoCA were assessed.
Results. In total, 44 patients were evaluated. Of these, 11 (25%) were identified by the ANAM as being impaired in comparison with 13 (29.5%) by the MoCA. The scores were significantly correlated (r = 0.57, p |
| doi_str_mv | 10.1177/0961203311405374 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902370620</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0961203311405374</sage_id><sourcerecordid>896833592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-bc84484e2e15ffda85c1826a1095bd98a083851ce24b89b5f7b4ed63062b78883</originalsourceid><addsrcrecordid>eNqFkctLw0AQxhdRbH3cPcnixVN0H9mX4EFKfUDBg3oOm82kpKS7NZsU-t-b0KpQEE8D8_3m-5gZhC4ouaFUqVtiJGWEc0pTIrhKD9CYpkolfZ8dovEgJ4M-QicxLgghnBp5jEaMSiUNI2N0PwlzX7XVGnCxiWXnXVsFjyuP32bTO1zAGuqwWoJvcSixxdE1AL7yc9yGUJ-ho9LWEc539RR9PE7fJ8_J7PXpZfIwSxw3ok1yp9NUp8CAirIsrBaOaiYtJUbkhdGWaK4FdcDSXJtclCpPoZCcSJYrrTU_Rddb31UTPjuIbbasooO6th5CFzNDGFc9Tf4ltZGac2FYT17tkYvQNb5fY4CEMowOwWQLuSbE2ECZrZpqaZtNRkk2vCDbf0E_crnz7fIlFD8D3zfvgWQLRDuH39A_Db8Az5uLBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>896579218</pqid></control><display><type>article</type><title>Cognitive dysfunction in SLE: development of a screening tool</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Adhikari, T ; Piatti, A ; Luggen, M</creator><creatorcontrib>Adhikari, T ; Piatti, A ; Luggen, M</creatorcontrib><description>Background. Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). There are two methods which have been used to detect CD in patients with SLE: traditional neuropsychological tests (NPT) and the Automated Neuropsychological Assessment Metrics (ANAM). Both are time-consuming and neither is readily available for screening purposes.
Purpose. The aim of our study was to evaluate the Montreal Cognitive Assessment (MoCA) test as a screening tool for detection of CD in SLE.
Methods. SLE patients fulfilling ACR criteria were administered the ANAM, a computerized test battery which measures various cognitive domains and the MoCA, a one-page, performance-based screening test designed to detect mild cognitive impairment in the elderly. With the ANAM as the gold standard, the performance characteristics of the MoCA were assessed.
Results. In total, 44 patients were evaluated. Of these, 11 (25%) were identified by the ANAM as being impaired in comparison with 13 (29.5%) by the MoCA. The scores were significantly correlated (r = 0.57, p < 0.001). Using the standard cutoff of 26, the sensitivity of MoCA was 83% and specificity 73%.
Conclusion. The MoCA appears to be a promising screening tool for the detection of CD in SLE both for epidemiologic studies and for routine clinical care.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203311405374</identifier><identifier>PMID: 21676920</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; African Americans ; Automation ; Cognition Disorders - diagnosis ; Cognition Disorders - etiology ; Cognitive ability ; Cognitive Dysfunction - diagnosis ; Cognitive Dysfunction - etiology ; Disease ; Female ; Geriatrics ; Humans ; Immunology ; Lupus ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - psychology ; Male ; Mental disorders ; Middle Aged ; Neuropsychological Tests - statistics & numerical data ; Neuropsychology ; Reproducibility of Results ; Rheumatology ; Systemic lupus erythematosus ; White people</subject><ispartof>Lupus, 2011-10, Vol.20 (11), p.1142-1146</ispartof><rights>The Author(s), 2011. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</rights><rights>SAGE Publications © Oct 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-bc84484e2e15ffda85c1826a1095bd98a083851ce24b89b5f7b4ed63062b78883</citedby><cites>FETCH-LOGICAL-c395t-bc84484e2e15ffda85c1826a1095bd98a083851ce24b89b5f7b4ed63062b78883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0961203311405374$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0961203311405374$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21676920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adhikari, T</creatorcontrib><creatorcontrib>Piatti, A</creatorcontrib><creatorcontrib>Luggen, M</creatorcontrib><title>Cognitive dysfunction in SLE: development of a screening tool</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Background. Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). There are two methods which have been used to detect CD in patients with SLE: traditional neuropsychological tests (NPT) and the Automated Neuropsychological Assessment Metrics (ANAM). Both are time-consuming and neither is readily available for screening purposes.
Purpose. The aim of our study was to evaluate the Montreal Cognitive Assessment (MoCA) test as a screening tool for detection of CD in SLE.
Methods. SLE patients fulfilling ACR criteria were administered the ANAM, a computerized test battery which measures various cognitive domains and the MoCA, a one-page, performance-based screening test designed to detect mild cognitive impairment in the elderly. With the ANAM as the gold standard, the performance characteristics of the MoCA were assessed.
Results. In total, 44 patients were evaluated. Of these, 11 (25%) were identified by the ANAM as being impaired in comparison with 13 (29.5%) by the MoCA. The scores were significantly correlated (r = 0.57, p < 0.001). Using the standard cutoff of 26, the sensitivity of MoCA was 83% and specificity 73%.
Conclusion. The MoCA appears to be a promising screening tool for the detection of CD in SLE both for epidemiologic studies and for routine clinical care.</description><subject>Adult</subject><subject>African Americans</subject><subject>Automation</subject><subject>Cognition Disorders - diagnosis</subject><subject>Cognition Disorders - etiology</subject><subject>Cognitive ability</subject><subject>Cognitive Dysfunction - diagnosis</subject><subject>Cognitive Dysfunction - etiology</subject><subject>Disease</subject><subject>Female</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Immunology</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - psychology</subject><subject>Male</subject><subject>Mental disorders</subject><subject>Middle Aged</subject><subject>Neuropsychological Tests - statistics & numerical data</subject><subject>Neuropsychology</subject><subject>Reproducibility of Results</subject><subject>Rheumatology</subject><subject>Systemic lupus erythematosus</subject><subject>White people</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkctLw0AQxhdRbH3cPcnixVN0H9mX4EFKfUDBg3oOm82kpKS7NZsU-t-b0KpQEE8D8_3m-5gZhC4ouaFUqVtiJGWEc0pTIrhKD9CYpkolfZ8dovEgJ4M-QicxLgghnBp5jEaMSiUNI2N0PwlzX7XVGnCxiWXnXVsFjyuP32bTO1zAGuqwWoJvcSixxdE1AL7yc9yGUJ-ho9LWEc539RR9PE7fJ8_J7PXpZfIwSxw3ok1yp9NUp8CAirIsrBaOaiYtJUbkhdGWaK4FdcDSXJtclCpPoZCcSJYrrTU_Rddb31UTPjuIbbasooO6th5CFzNDGFc9Tf4ltZGac2FYT17tkYvQNb5fY4CEMowOwWQLuSbE2ECZrZpqaZtNRkk2vCDbf0E_crnz7fIlFD8D3zfvgWQLRDuH39A_Db8Az5uLBQ</recordid><startdate>201110</startdate><enddate>201110</enddate><creator>Adhikari, T</creator><creator>Piatti, A</creator><creator>Luggen, M</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>201110</creationdate><title>Cognitive dysfunction in SLE: development of a screening tool</title><author>Adhikari, T ; Piatti, A ; Luggen, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-bc84484e2e15ffda85c1826a1095bd98a083851ce24b89b5f7b4ed63062b78883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>African Americans</topic><topic>Automation</topic><topic>Cognition Disorders - diagnosis</topic><topic>Cognition Disorders - etiology</topic><topic>Cognitive ability</topic><topic>Cognitive Dysfunction - diagnosis</topic><topic>Cognitive Dysfunction - etiology</topic><topic>Disease</topic><topic>Female</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Immunology</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - psychology</topic><topic>Male</topic><topic>Mental disorders</topic><topic>Middle Aged</topic><topic>Neuropsychological Tests - statistics & numerical data</topic><topic>Neuropsychology</topic><topic>Reproducibility of Results</topic><topic>Rheumatology</topic><topic>Systemic lupus erythematosus</topic><topic>White people</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adhikari, T</creatorcontrib><creatorcontrib>Piatti, A</creatorcontrib><creatorcontrib>Luggen, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adhikari, T</au><au>Piatti, A</au><au>Luggen, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cognitive dysfunction in SLE: development of a screening tool</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2011-10</date><risdate>2011</risdate><volume>20</volume><issue>11</issue><spage>1142</spage><epage>1146</epage><pages>1142-1146</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Background. Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). There are two methods which have been used to detect CD in patients with SLE: traditional neuropsychological tests (NPT) and the Automated Neuropsychological Assessment Metrics (ANAM). Both are time-consuming and neither is readily available for screening purposes.
Purpose. The aim of our study was to evaluate the Montreal Cognitive Assessment (MoCA) test as a screening tool for detection of CD in SLE.
Methods. SLE patients fulfilling ACR criteria were administered the ANAM, a computerized test battery which measures various cognitive domains and the MoCA, a one-page, performance-based screening test designed to detect mild cognitive impairment in the elderly. With the ANAM as the gold standard, the performance characteristics of the MoCA were assessed.
Results. In total, 44 patients were evaluated. Of these, 11 (25%) were identified by the ANAM as being impaired in comparison with 13 (29.5%) by the MoCA. The scores were significantly correlated (r = 0.57, p < 0.001). Using the standard cutoff of 26, the sensitivity of MoCA was 83% and specificity 73%.
Conclusion. The MoCA appears to be a promising screening tool for the detection of CD in SLE both for epidemiologic studies and for routine clinical care.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>21676920</pmid><doi>10.1177/0961203311405374</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 2011-10, Vol.20 (11), p.1142-1146 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902370620 |
| source | Access via SAGE; MEDLINE |
| subjects | Adult African Americans Automation Cognition Disorders - diagnosis Cognition Disorders - etiology Cognitive ability Cognitive Dysfunction - diagnosis Cognitive Dysfunction - etiology Disease Female Geriatrics Humans Immunology Lupus Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - psychology Male Mental disorders Middle Aged Neuropsychological Tests - statistics & numerical data Neuropsychology Reproducibility of Results Rheumatology Systemic lupus erythematosus White people |
| title | Cognitive dysfunction in SLE: development of a screening tool |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T17%3A51%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cognitive%20dysfunction%20in%20SLE:%20development%20of%20a%20screening%20tool&rft.jtitle=Lupus&rft.au=Adhikari,%20T&rft.date=2011-10&rft.volume=20&rft.issue=11&rft.spage=1142&rft.epage=1146&rft.pages=1142-1146&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203311405374&rft_dat=%3Cproquest_cross%3E896833592%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=896579218&rft_id=info:pmid/21676920&rft_sage_id=10.1177_0961203311405374&rfr_iscdi=true |